Advertisement
U.S. markets open in 4 hours 41 minutes
  • S&P Futures

    5,306.50
    -1.75 (-0.03%)
     
  • Dow Futures

    40,147.00
    +3.00 (+0.01%)
     
  • Nasdaq Futures

    18,496.50
    -7.25 (-0.04%)
     
  • Russell 2000 Futures

    2,134.10
    -4.30 (-0.20%)
     
  • Crude Oil

    81.87
    +0.52 (+0.64%)
     
  • Gold

    2,216.60
    +3.90 (+0.18%)
     
  • Silver

    24.57
    -0.18 (-0.74%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.97
    +0.19 (+1.49%)
     
  • GBP/USD

    1.2609
    -0.0029 (-0.23%)
     
  • USD/JPY

    151.3620
    +0.1160 (+0.08%)
     
  • Bitcoin USD

    70,805.83
    +1,037.79 (+1.49%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,953.96
    +21.98 (+0.28%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Allergan, facing shareholder demands, calls special meeting for Dec. 18

Aug 26 (Reuters) - Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.

Although Allergan set a date for the meeting, it said in a Delaware court filing that it will review the validity of the shareholder requests for the meeting on Sept. 4.

California-based Allergan, the maker of Botox anti-wrinkle skin injections, is trying to fend off a $49 billion hostile takeover by Canada's Valeant. Ackman's Pershing Square Capital Management, Allergan's biggest shareholder, hopes to see a revamped Allergan board that would be willing to negotiate with Valeant.

Ackman said on Friday that investors holding 31 percent of Allergan shares had asked for the meeting. Pershing Square said it also filed a lawsuit in Delaware to require Allergan to schedule the meeting, anticipating that the company would likely fight doing so.

At least 25 percent of shareholder support is necessary under Allergan's bylaws to call the meeting.

(Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Leslie Adler)

Advertisement